To determine whether AXT properties affect the response of GBM cell lines to TRAIL, we pretreated GBM cell lines with 2.5 to 10 μM AXT for 3 h prior to TRAIL treatment for 24 h (Figure 2). The gene discussed is TNFSF10; the disease is glioblastoma.